Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies

Basit Öğe Kaydı
dc.contributor.authorCakir, Mehtap
dc.contributor.authorGrossman, Ashley B.
dc.date.accessioned2020-03-26T17:39:14Z
dc.date.available2020-03-26T17:39:14Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractMedullary thyroid cancer (MTC) arises from neural-crest-derived parafollicular C cells of the thyroid gland and accounts for approximately 4% of all thyroid cancers. Up to 25-30% of MTC cases occur as inherited disorders while the remaining cases represent the sporadic form of the disease. In this review, the structure and signalling properties of the RET protooncogene in its wild-type and mutant forms, and its role in hereditary and sporadic MTC, are discussed. A full data search was performed through PubMed over the years 2000-2008 with the key words 'medullary thyroid cancer, treatment, molecular biology, RET, molecular mechanism', and all relevant publications have been included, together with selected publications prior to that date. We also review novel therapies for metastatic MTC, especially the tyrosine kinase inhibitors which have activity at multiple receptor subtypes, and summarize the current ongoing trials in this area. While such tyrosine kinase inhibitors, particularly those affecting RET activity such as vandetanib, sorafenib and sunitinib, are promising, the low rate of partial responses and absence of complete responses in all of the various trials of monotherapy emphasize the need for new and more effective single agents or combinations of therapeutic agents with acceptable toxicity. Copyright (C) 2009 S. Karger AG, Baselen_US
dc.description.sponsorshipSociety of Endocrinology and Metabolism of Turkey; London School of Medicine and Dentistry, Londonen_US
dc.description.sponsorshipM. C. is currently at Selcuk University, Meram School of Medicine, Division of Endocrinology and Metabolism, Konya, Turkey, and was awarded a grant by The Society of Endocrinology and Metabolism of Turkey to study at the Centre for Endocrinology, Barts and The London School of Medicine and Dentistry, London.en_US
dc.identifier.doi10.1159/000220827en_US
dc.identifier.endpage348en_US
dc.identifier.issn0028-3835en_US
dc.identifier.issn1423-0194en_US
dc.identifier.issue4en_US
dc.identifier.pmid19468197en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage323en_US
dc.identifier.urihttps://dx.doi.org/10.1159/000220827
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23674
dc.identifier.volume90en_US
dc.identifier.wosWOS:000272322100001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKARGERen_US
dc.relation.ispartofNEUROENDOCRINOLOGYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectMedullary thyroid canceren_US
dc.subjectPathogenesisen_US
dc.subjectMolecular therapyen_US
dc.titleMedullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapiesen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu